Compounds derived from epigallocatechin-3-gallate (EGCG) as a novel approach to the prevention of viral infections

Inflammation and Allergy - Drug Targets

Volumn 14, Issue 1, 2015, Pages 13-18

  Hsu, Stephen ^a  

^a AUGUSTA UNIVERSITY   (United States)

Author keywords

EGCG; Green tea; Sanitizer; Viral infections

Indexed keywords

CATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HAND SANITIZER; POLYPHENOL DERIVATIVE; THEAFLAVIN; ALCOHOL DERIVATIVE;

CAMELLIA SINENSIS; CLINICAL TRIAL (TOPIC); EBOLA HEMORRHAGIC FEVER; HUMAN; INFLUENZA; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VIRION; VIRUS ENTRY; VIRUS INFECTION; ANALOGS AND DERIVATIVES; ANIMAL; DISINFECTION; HAND DISINFECTION; IMMUNOLOGY; VIRUS DISEASES;

ALCOHOLS; ANIMALS; CAMELLIA SINENSIS; CATECHIN; DISINFECTION; HAND DISINFECTION; HUMANS; VIRUS DISEASES;

EID: 84953406142     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528114666151022150122     Document Type: Review

References (46)

1. Larson, E.L.; Cohen, B.; Baxter, K.A. Analysis of alcohol-based hand sanitizer delivery systems: efficacy of foam, gel, and wipes against influenza A (H1N1) virus on hands. Am. J. Infect. Control., 2012, 40(9), 806-809.
2. Thompson, W.W.; Shay, D.K.; Weintraub, E.; Brammer, L.; Bridges, C.B.; Cox, N.J.; Fukuda, K. Influenza-associated hospitalizations in the United States. Update: Influenza activity-- United States, September 28, 2014-February 21, 2015.
3. D'Mello, T.; Brammer, L.; Blanton, L.; Kniss, K.; Smith, S.; Mustaquim, D.; Steffens, C.; Dhara, R.; Cohen, J.; Chaves, S.S.; Finelli, L.; Bresee, J.; Wallis, T.; Xu, X.; Abd, Elal, A.I.; Gubareva, L.; Wentworth, D.; Villanueva, J.; Katz, J.; Jernigan, D. Centers for Disease Control and Prevention (CDC). MMWR Morb. Mortal. Wkly. Rep., 2015, 64(8), 206-212.
4. Stebbins, S.; Cummings, D.A.; Stark, J.H.; Vukotich, C.; Mitruka, K.; Thompson, W.; Rinaldo, C.; Roth, L.; Wagner, M.; Wisniewski, S.R.; Dato, V.; Eng, H.; Burke, D.S. Reduction in the incidence of influenza A but not influenza B associated with use of hand sanitizer and cough hygiene in schools: a randomized controlled trial. Pediatr. Infect. Dis. J,. 2011, 30(11), 921-926.
5. Lin, C.M.; Wu, F.M.; Kim, H.K.; Doyle, M.P.; Michael, B.S.; Williams, L.K. A comparison of hand washing techniques to remove Escherichia coli and caliciviruses under natural or artificial fingernails. J. Food Prot., 2003, 66(12), 2296-2301.
6. Sandora, T.J.; Shih, M.C.; Goldmann, D.A. Reducing absenteeism from gastrointestinal and respiratory illness in elementary school students: a randomized, controlled trial of an infection-control intervention. Pediatrics. 2008, 121(6), e1555-1562.
7. Liu, P.; Yuen, Y.; Hsiao, H.M.; Jaykus, L.A.; Moe, C. Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. Appl. Environ. Microbiol., 2010, 76(2), 394-399.
8. Blaney, D.D.; Daly, E.R.; Kirkland, K.B.; Tongren, J.E.; Kelso, P.T.; Talbot, E.A. Use of alcohol-based hand sanitizers as a risk factor for norovirus outbreaks in long-term care facilities in northern New England: December 2006 to March 2007. Am. J. Infect. Control., 2011, 39(4), 296-301.
9. Satterwhite, C.L.; Torrone, E.; Meites, E.; Dunne, E.F.; Mahajan, R.; Ocfemia, M.C.; Su, J.; Xu, F.; Weinstock, H. Sexually transmitted infections among US women and men: prevalence and incidence estimates. Sex Transm. Dis., 2013, 40(30), 187-193
10. CDC. Sexually Transmitted Disease Surveillance, 2013. Atlanta, GA: Department of Health and Human Services; December 2014.
11. Bradley, H.; Markowitz, L.; Gibson, T.; McQuillan, G. Seroprevalence of Herpes Simplex Virus Types 1 and 2-United States, 1999-2010. J. Infect. Dis., 2014, 209(3), 325-333.
12. Reece, M.; Herbenick, D.; Schick, V.; Sanders, S.A.; Dodge, B.; Fortenberry, J.D. Condom use rates in a national probability sample of males and females ages 14 to 94 in the United States. J. Sex. Med., 2010, 7 (Suppl 5), 266-276.
13. Sedgh, G.; Finer, L.B.; Bankole, A.; Eilers, M.A.; Singh, S. Adolescent pregnancy, birth, and abortion rates across countries: levels and recent trends. J. Adolesc. Health, 2015, 56(2), 223-230.
14. Czerwinski, S.E.; Cozean, J,; Cozean, C. Novel water-based antiseptic lotion demonstrates rapid, broad-spectrum kill compared with alcohol antiseptic. J. Infect. Public Health, 2014, 7(3), 199- 204.
15. Dao, H. Jr.; Fricker, C.; Nedorost, S.T. Sensitization prevalence for benzalkonium chloride and benzethonium chloride. Dermatitis, 2012, 23(4), 162-166.
16. Xue, Y.; Zhang, S.; Tang, M.; Zhang, T.; Wang, Y.; Hieda, Y.; Takeshita, H. Comparative study on toxic effects induced by oral or intravascular administration of commonly used disinfectants and surfactants in rats. J. Appl. Toxicol., 2012, 32(7), 480-487.
17. Pinheiro, R.; Panfil, C.; Schrage, N.; Dutescu, R.M. The Impact of Glaucoma Medications on Corneal Wound Healing. J. Glaucoma, 2015, Jul 10. [Epub ahead of print]
18. Matsumoto, Y.; Kaihatsu, K.; Nishino, K.; Ogawa, M.; Kato, N.; Yamaguchi, A. Antibacterial and antifungal activities of new acylated derivatives of epigallocatechin gallate. Front Microbiol., 2012, 3, 53.
19. Zhao, C.; Liu, S.; Li, C.; Yang, L.; Zu, Y. In vitro evaluation of the antiviral activity of the synthetic epigallocatechin gallate analogepigallocatechin gallate (EGCG) palmitate against porcine reproductive and respiratory syndrome virus. Viruses, 2014, 6(2), 938-950.
20. Mori, S.; Miyake, S.; Kobe, T.; Nakaya, T.; Fuller, S.D.; Kato, N.; Kaihatsu, K. Enhanced anti-influenza A virus activity of (-)- epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length. Bioorg. Med. Chem. Lett., 2008, 18(14), 4249-4252.
21. Paterson, L.; Anderson, E.A. The renaissance of natural products as drug candidates. Science, 2005, 310 (5747), 451-453.
22. Hsu, S.; Dickinson, D. Green tea and skin protection: mechanism of action and practical applications. Household and Personal Care, 2009, June 33-36.
23. Chen, P.; Dickinson, D.; Hsu, S. Lipid-soluble Green Tea Polyphenols: Stabilized for Effective Formulation. In: Handbook of Green Tea and Health Research. McKinley, H., Jamieson, M., Eds. Nova Science Publishers, Inc. 2009.
24. Kaihatsu, K.; Mori, S.; Matsumura, H.; Daidoji, T.; Kawakami, C.; Kurata, H.; Nakaya, T.; Kato, N. Broad and potent anti-influenza virus spectrum of epigallocatechin-3-O-gallate-monopalmitate. J. Mol. Genet. Med., 2009, 3(2), 195-197.
25. Steinmann, J.; Buer, J.; Pietschmann, T.; Steinmann, E. Antiinfective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol., 2013, 168, 1059-1073.
26. Colpitts, C.C.; Schang, L.M. A small molecule inhibits virion attachment to heparan sulfate- or sialic acid-containing glycans. J. Virol., 2014, 88, 7806-7817.
27. de Oliveira, A.; Adams, S.D.; Lee, L.H.; Murray, S.R.; Hsu, S.D.; Hammond, J.R.; Dickinson, D.; Chen, P.; Chu, T.C. Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate. Food Chem. Toxicol., 2012, 52, 207-215.
28. Reid, S.P.; Shurtleff, A.C.; Costantino, J.A.; Tritsch, S.R.; Retterer, C.; Spurgers, K.B.; Bavari. S. HSPA5 is an essential host factor for Ebola virus infection. Antiviral Res., 2014, 109, 171-174.
29. Xu, J.; Wang, J.; Deng, F.; Hu, Z.; Wang, H. Green tea extract and its major component epigallocatechin gallate inhibits hepatitisB virus in vitro. Antiviral Res., 2008, 78(3), 242-249.
30. Ciesek, S.; von Hahn, T.; Colpitts, C.C.; Schang, L.M.; Friesland, M.; Steinmann, J.; Manns, M.P.; Ott, M.; Wedemeyer, H.; Meuleman, P.; Pietschmann, T.; Steinmann, E. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology, 2011, 54(6), 1947-1955.
31. Calland, N.; Sahuc, ME.; Belouzard, S.; Pene, V.; Bonnafous, P.; Mesalam, A.A.; Deloison, G.; Descamps, V.; Sahpaz, S.; Wychowski, C.; Lambert, O.; Brodin, P.; Duverlie, G.; Meuleman, P.; Rosenberg, A.R.; Dubuisson, J.; Rouille, Y.; Seron, K. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J. Virol., 2015, 89(19), 10053-10063
32. Huang, HC.; Tao, M.H.; Hung, TM.; Chen, J.C.; Lin, Z.J.; Huang, C. (-)-Epigallocatechin-3-gallate inhibits entry of hepatitis B virus into hepatocytes. Antiviral Res., 2014, 111, 100-111.
33. Williamson, M.P.; McCormick, T.G.; Nance, C.L.; Shearer, W.T. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy. J. Allergy Clin. Immunol., 2006, 118(6), 1369-1374.
34. Kawai, K.; Tsuno, N.H.; Kitayama, J.; Okaji, Y.; Yazawa, K.; Asakage, M.; Hori, N.; Watanabe, T.; Takahashi, K.; Nagawa, H. Epigallocatechin gallate, the main component of tea polyphenol, binds to CD4 and interferes with gp120 binding. J. Allergy Clin. Immunol., 2003, 112(5), 951-957.
35. Nance, C.L.; Siwak, E.B.; Shearer, W.T. Preclinical development of the green tea catechin, epigallocatechin gallate, as anHIV-1 therapy. J. Allergy Clin. Immunol., 2009, 123(2), 459-465.
36. Jiang, F.; Chen, W.; Yi, K.; Wu. Z.; Si, Y.; Han, W.; Zhao, Y. The evaluation of catechins that contain a galloyl moiety as potential HIV-1 integrase inhibitors. Clin. Immunol., 2010, 137(3), 347-356.
37. Ahn, W.S.; Yoo, J.; Huh, S.W.; Kim, C.K.; Lee, J.M.; Namkoong, S.E.; Bae, S.M.; Lee, I.P. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev., 2003, 12(5), 383-390.
38. He, L.; Zhang, E.; Shi, J.; Li, X.; Zhou, K.; Zhang, Q.; Le, A.D.; Tang, X. (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α. Cancer Chemother. Pharmacol., 2013, 71(3), 713-725.
39. Hsu, S. Green tea and the skin. J. Am. Acad. Dermatol., 2005, 52(6), 1049-1059.
40. Chen, P.; Wang, H.; Du, Q.; Ito, Y. Purification of long-chain fatty acid ester of epigallocatechin-3-O-gallate by high-speed countercurrent chromatography. J. Chromatogr., 2002, 982(1), 163-165.
41. Chen, P.; Tan, Y.; Sun, D.; Zheng, X.M. A novel long-chain acylderivative of epigallocatechin-3-O-gallate prepared and purified from green tea polyphenols. J. Zhejiang Univ. Sci., 2003, 4(6), 714- 718.
42. Chen, P.; Sun, D. A new catechin derivative as antioxidant for vegetable oil. J. Chinese Cereals Oils Assoc., 2003, 18(5), 77-78.
43. Sun, D.; Zhang, S.; Zhu, Y.; Wang, Y. Study on antioxidant activity of lipid-soluble tea polyphenol in lipid. Cereals Oil (Chinese)., 2014, 27, 1, 42
44. Zhao, M.; Zheng, R.; Jiang, J.; Dickinson, D.; Fu, B.; Chu, T.; Lee, L.; Pearl, H.; Hsu, S. Topical lipophilic epigallocatechin-3-gallate on herpes labialis: a phase ii clinical trial of AverTeaX formula. Oral Surg. Oral Med. Oral Pathol. Oral Radiol., 2015 [e-pub ahead of print].
45. Ho, H.Y.; Cheng, M.L.; Weng, S.F.; Leu, Y.L.; Chiu, D.T. Antiviral effect of epigallocatechin gallate on enterovirus 71. J. Agric. Food Chem., 2009, 57(14), 6140-6147.
46. Muller, P.; Downard, K.M. Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry. J. Pharm. Biomed. Anal., 2015, 111, 222-230.